NKF Statement Regarding FDA Approval of Modified Language on Labels for ESAs

(NEW YORK, NY)—June 27, 2011—The new label for the use of erythropoiesis-stimulating agents (ESAs), is consistent with the National Kidney Foundation's position that medical decisions of all kinds should be made jointly by the patient and the health care professional who is managing his or her care, taking into account the latest and most credible information about risks and benefits. These include the impact on candidacy for transplant and the difference between anemia therapy for individuals on dialysis and people in other stages of chronic kidney disease.